Bicycle Therapeutics plc (BCYC)
Automate Your Wheel Strategy on BCYC
With Tiblio's Option Bot, you can configure your own wheel strategy including BCYC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCYC
- Rev/Share 0.4089
- Book/Share 8.9242
- PB 0.8001
- Debt/Equity 0.0016
- CurrentRatio 10.6639
- ROIC -0.4139
- MktCap 494719947.0
- FreeCF/Share -3.49
- PFCF -2.0454
- PE -1.9741
- Debt/Assets 0.0013
- DivYield 0
- ROE -0.3554
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BCYC | Truist | -- | Hold | -- | $19 | Nov. 24, 2025 |
| Downgrade | BCYC | RBC Capital Mkts | Outperform | Sector Perform | -- | $11 | Oct. 31, 2025 |
| Initiation | BCYC | RBC Capital Mkts | -- | Outperform | -- | $35 | Sept. 6, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bicycle Therapeutics plc ("Bicycle" or the "Company") (NASDAQ: BCYC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
ATTENTION BCYC Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
Published: November 18, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 18, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Bicycle Therapeutics plc ("Bicycle Therapeutics plc") (NASDAQ: BCYC) concerning possible violations of federal securities laws. On October 31, 2025, RBC Capital Markets analyst Leonid Timashev downgraded Bicycle to Sector Perform from Outperform, citing delays in development of zelenectide pevedotin, which is in phase 2/3 development for metastatic urothelial cancer, due to pushing dose selection to the first quarter of 2026.
Read More
Bicycle Therapeutics Plc (BCYC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Bicycle Therapeutics plc (NASDAQ:BCYC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Kevin Lee - CEO & Executive Director Jennifer Perry - Chief Strategy Officer & Head of Commercial Alethia Young - Chief Financial Officer Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Hello, everyone. I'm Max Skor, a biotech analyst with Morgan Stanley, and I'm happy to welcome Bicycle Therapeutics, specifically Kevin Lee, CEO; Alethia Young, CFO; and Jennifer Perry, Chief Strategy Officer.
Read More
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago. Poster Presentation Details: Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin.
Read More
Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses.
Read More
About Bicycle Therapeutics plc (BCYC)
- IPO Date 2019-05-23
- Website https://www.bicycletherapeutics.com
- Industry Biotechnology
- CEO Kevin Lee
- Employees 305